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Phosphorylation and activation of heart PFK-2 by AMPK has a
role in the stimulation of glycolysis during ischaemia
A-S. Marsin*†, L. Bertrand*†, M.H. Rider*, J. Deprez*, C. Beauloye*,
M.F. Vincent‡, G. Van den Berghe‡, D. Carling§ and L. Hue*
Background: The role of protein phosphorylation in the Pasteur effect — the
phenomenon whereby anaerobic conditions stimulate glycolysis — has not been
addressed. The AMP-activated protein kinase (AMPK) is activated when the
oxygen supply is restricted. AMPK acts as an energy-state sensor and inhibits
key biosynthetic pathways, thus conserving ATP. Here, we studied whether
AMPK is involved in the Pasteur effect in the heart by phosphorylating and
activating 6-phosphofructo-2-kinase (PFK-2), the enzyme responsible for the
synthesis of fructose 2,6-bisphosphate, a potent stimulator of glycolysis.
Results: Heart PFK-2 was phosphorylated on Ser466 and activated by AMPK
in vitro. In perfused rat hearts, anaerobic conditions or inhibitors of oxidative
phosphorylation (oligomycin and antimycin) induced AMPK activation, which
correlated with PFK-2 activation and with an increase in fructose
2,6-bisphosphate concentration. Moreover, in cultured cells transfected with
heart PFK-2, oligomycin treatment resulted in a parallel activation of endogenous
AMPK and PFK-2. In these cells, the activation of PFK-2 was due to the
phosphorylation of Ser466. A dominant-negative construct of AMPK abolished
the activation of endogenous and cotransfected AMPK, and prevented both the
activation and phosphorylation of transfected PFK-2 by oligomycin.
Conclusions: AMPK phosphorylates and activates heart PFK-2 in vitro and in
intact cells. AMPK-mediated PFK-2 activation is likely to be involved in the
stimulation of heart glycolysis during ischaemia.
Background
To maintain its function, the heart requires a constant supply
of fuels and oxygen. When the oxygen supply is not limited
(normoxic conditions), these fuels are completely oxidised
in the mitochondria (reviewed in [1]). Myocardial ischaemia
induces a shift to anaerobic metabolism, with a rapid stim-
ulation of glycolysis [2,3]. This anaerobic stimulation of
glycolysis, called the Pasteur effect, can occur in different
mammalian tissues. The role of protein phosphorylation in
this phenomenon has not been addressed. In the heart, a
protein kinase that is activated by ischaemia could be
responsible for the stimulation of glycolysis in this condition. 
The AMP-activated protein kinase (AMPK) is a protein
kinase that is activated in anaerobic conditions. AMPK is a
heterotrimeric protein composed of a catalytic subunit (α)
and two regulatory subunits (β and γ) [4,5]. Isoforms of all
three subunits have been identified [6,7], but the physiolog-
ical significance of the isoforms is unclear. In the heart, the
catalytic α2 isoform is more abundant than α1 [6]. AMPK is
activated by an increase in the intracellular AMP:ATP ratio
and so acts as a sensor of the energy state (‘fuel gauge’) of
the cell (for a review, see [8]). The AMP:ATP ratio is
known to increase when the oxygen supply is restricted or
in the presence of inhibitors of mitochondrial oxidative
phosphorylation. In various tissues (liver, adipose tissue and
skeletal muscle), AMPK phosphorylates and inactivates
several key enzymes in energy-consuming biosynthetic
pathways, thereby conserving ATP. This is the case for
acetyl-CoA carboxylase (ACC), 3-hydroxy-3-methylglutaryl-
CoA reductase [9], glycogen synthase [10] and creatine
kinase [11], which control the synthesis of fatty acids, cho-
lesterol, glycogen and phosphocreatine, respectively. In
skeletal and cardiac muscle, AMPK is thought to mediate
the recruitment of glucose transporters (GLUT4) by an
unknown mechanism that is distinct from that of insulin
[12,13]. Our hypothesis is that myocardial hypoxia stimu-
lates glycolysis in a concerted manner, which involves
GLUT4 recruitment and 6-phosphofructo-2-kinase (PFK-2)
activation, and is mediated by AMPK.
PFK-2 is a bifuntional enzyme, termed PFK-2/fructose-
2,6-bisphosphatase (FBPase-2), which controls the synthesis
and degradation of fructose 2,6-bisphosphate, respec-
tively. Fructose 2,6-bisphosphate is a potent stimulator of
6-phosphofructo-1-kinase (PFK-1), a key enzyme of glyco-
lysis and, as such, it is considered as a ubiquitous glycolytic
signal (for a review, see [14]). Distinct isozymes of PFK-2
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exist in mammalian tissues. They are encoded by different
genes and differ in molecular mass, kinetic and immunolog-
ical properties, and phosphorylation by protein kinases (for
reviews, see [14,15]). The heart (H) isozyme contains a
carboxy-terminal regulatory domain that is absent in the
liver (L) isozyme and can be phosphorylated on both
Ser466 and Ser483 in vitro by protein kinase B (PKB), cyclic
AMP-dependent protein kinase (PKA), p70 ribosomal S6
kinase (p70S6k) and mitogen-activated protein kinase-acti-
vated protein kinase–1 (MAPKAPK-1) [16]. Phosphoryla-
tion activates PFK-2 with no effect on FBPase-2 activity.
Phosphorylation of Ser466 is sufficient to increase the Vmax,
whereas phosphorylation of both Ser466 and Ser483 is
required to decrease the Km for fructose 6-phosphate of
PFK-2 [17]. In accordance with its capacity to be phospho-
rylated by several protein kinases, PFK-2 is activated in
hearts stimulated by adrenaline or insulin, or submitted to
high workload, and correlates with the stimulation of glycol-
ysis observed under these conditions [1].
Here, we studied whether heart PFK-2 could be a substrate
of AMPK and we investigated the effect of anaerobic condi-
tions on AMPK and PFK-2 activity in perfused rat hearts.
We also transfected human embryonic kidney (HEK)-293
cells with cDNA constructs encoding recombinant wild-type
bovine heart PFK-2 and both wild-type and dominant-nega-
tive forms of AMPK, in order to assess the role of AMPK in
the activation of heart PFK-2 in anaerobic conditions.
Results
Phosphorylation and activation of heart PFK-2 in vitro
by AMPK
Recombinant bovine heart PFK-2 carrying a carboxy-termi-
nal hexa-histidine tag (His6–PFK-2) was phosphorylated
by rabbit liver AMPK with a stoichiometry close to 1 mole
phosphate incorporated per mole enzyme subunit. The
rate of phosphorylation was stimulated by 0.2 mM AMP
(Figure 1a) and correlated with PFK-2 activation
(Figure 1b). Similarly, protein phosphatase 2A (PP2A)-
mediated dephosphorylation of PFK-2 that had been pre-
viously phosphorylated by AMPK correlated with PFK-2
inactivation (Figure 1c). Such a correlation between acti-
vation and phosphorylation has already been described for
heart PFK-2 phosphorylated by PKB, p70S6k and
MAPKAPK-1 [16]. PFK-2 activation by AMPK resulted
from a 2.5-fold increase in Vmax (49 ± 5 to 123 ± 10 mU/mg
protein; n = 3), with little (less than 20%) or no change in
Km for fructose 6-phosphate and MgATP or in IC50 for
magnesium citrate (see Supplementary material). In con-
trast, phosphorylation of His6–PFK-2 by PKB increased
the Vmax (twofold) but also decreased the Km for fructose
6-phosphate (twofold) and decreased the sensitivity
towards magnesium citrate inhibition (twofold). Phospho-
rylation of His6–PFK-2 did not affect FBPase-2 activity
(see Supplementary material).
To identify the site(s) phosphorylated by AMPK, His6–
PFK-2 was maximally phosphorylated with Mg[γ-32P]ATP
and AMPK. After purification by SDS–PAGE and diges-
tion with trypsin, peptides were separated by reversed-
phase high-pressure liquid chromatography (HPLC). A
single radioactive peak was detected (Figure 2a) and its
radioactivity was decreased (twofold) when phosphoryla-
tion was performed without AMP (data not shown). The
elution time of this peak was the same (Figure 2a,b) as
that of the first peak obtained after phosphorylation of
His6–PFK-2 by PKB and which contained phosphorylated
Ser466 [17]. The residue phosphorylated by AMPK was
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Time-dependent changes in phosphorylation state and activity of
His6–PFK-2 incubated with (a,b) AMPK and (c) PP2A. (a) Purified wild-
type His6–PFK-2 (0.16 mg/ml) was incubated with 0.1 mM
Mg[γ-32P]ATP and purified AMPK (0.6 U/ml) with (shaded squares) or
without (unshaded squares) 0.2 mM AMP in a final volume of 50 µl.
Unshaded circles correspond to a control incubated without AMPK. At
the indicated times, aliquots (5 µl) were removed for SDS–PAGE and
phosphorimaging for measurement of 32P incorporation. (b) Same
protocol as in (a) with 1 mM MgATP (non-radioactive) in a final volume
of 0.1 ml with (shaded triangles) or without (unshaded triangles)
0.2 mM AMP. At the indicated times, aliquots (10 µl) were removed for
PFK-2 assay. The results are the means ± SEM for three separate
determinations. (c) His6–PFK-2 was first phosphorylated as described
above and then dephosphorylated with PP2A (50 U/ml). Aliquots were
removed for the measurement of 32P incorporation (squares) and PFK-2
activity (triangles); results are the means for two separate experiments.
identified by analysing the labelled peak by matrix-
assisted laser desorption-ionisation mass spectrometry
(MALDI-MS), nanoelectro-spray ionisation tandem mass
spectrometry (nanoESI-MS/MS) and by solid-phase
sequencing (Figure 2c). The labelled peptide contained
the sequence 464RNSFTPLSSSNTIR477 in which the
burst of radioactivity occurred at Ser466 (Figure 2c). In
agreement with the identification of Ser466 as the phos-
phorylated residue, a constitutively active S466E mutant of
His6–PFK-2 was not phosphorylated and could not be
further activated by AMPK (data not shown). This mutant
could, however, be phosphorylated by PKB on Ser483 [17].
The recognition motif for phosphorylation by AMPK, as
deduced from sequences surrounding its known phospho-
rylated sites, contains hydrophobic residues at P–5 and P+4
(where P is the phosphorylated site) and a single basic
residue at P–3 or P–4 [8]. This motif differs slightly from
that in endothelial nitric oxide synthase (eNOS), which
contains hydrophobic residues at P–4 and P+3 [18]. The
phosphorylation site in heart PFK-2 (VRMRRNSFTPLS;
the phosphorylated Ser is bold and italicized) shares simi-
larities with both motifs. It contains hydrophobic residues
at P–4 and P+4 and a basic residue at P–3.
In the experiments described above, we used AMPK puri-
fied from rabbit liver, which contains both α1βγ and α2βγ
complexes, similar to the enzyme purified from rat liver
[19]. To study the relative specificity of the individual iso-
forms, we isolated α1βγ- and α2βγ-specific complexes by
immunoprecipitation from rat liver and compared their
activity using either His6–PFK-2 or ACC as a substrate.
Both isoforms phosphorylated His6–PFK-2 at the same
rate, which was about half the rate of phosphorylation of
ACC (data not shown). We also compared the kinetic
properties towards SAMS, a known synthetic substrate
derived from ACC [20], and the peptide MR6 (containing
Ser466 of cardiac PFK-2). The Vmax and Km values for
SAMS were the same for both isoforms. For the MR6
peptide, the Vmax and Km of α2βγ were twice that of α1βγ.
The latter differences compensated for each other, such
that the value of kcat/Km (sometimes called ‘catalytic effi-
ciency’) was the same. Nevertheless, this value was 3–4
times lower than for SAMS, confirming that ACC is a
better substrate of AMPK than His6–PFK-2 (see Supple-
mentary material). We also studied the kinetic properties
of the AMPK isoforms towards a peptide containing a
serine residue in a sequence homologous to that surround-
ing Ser466 in heart PFK-2. This sequence is found in a
PFK-2 isozyme present in some tumour cells [21] and pla-
centa [22]. This peptide (MR47) was equally phosphory-
lated by both AMPK isoforms, although the efficiency was
about 10 times less than that observed with the MR6
peptide (see Supplementary material). 
Activation of AMPK and PFK-2 in perfused rat hearts
Perfused rat hearts were submitted to different periods of
no-flow ischaemia to study whether AMPK activation
would correlate with PFK-2 activation and with an
increase in fructose 2,6-bisphosphate concentration.
AMPK, which was almost completely inactive under
aerobic conditions, was activated 10-fold after 10 minutes
of ischaemia (both AMPK isoforms were activated) and
its activity returned towards basal levels after 30 minutes
of ischaemia (Figure 3a). Ischaemia activated PFK-2 and
increased fructose 2,6-bisphosphate concentration, both
processes following AMPK activation with a slight delay
(Figure 3). The activation of AMPK and PFK-2 by
ischaemia was transient. Remarkably, this correlated with
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HPLC profile and solid-phase sequencing of 32P-labelled tryptic
peptides of His6–PFK-2 phosphorylated in vitro by AMPK and PKB.
His6–PFK-2 was phosphorylated by (a) AMPK or (b) PKB and 0.1 mM
Mg[γ-32P]ATP. After digestion with trypsin, peptides were separated by
reverse-phase HPLC using a linear gradient of acetonitrile (dashed
line). The means of two separate experiments are shown. The peaks
corresponding to the peptides containing phosphorylated Ser466 and
Ser483 (pSer466, pSer483) are indicated in (b). (c) The radioactive
peptide from His6–PFK-2 phosphorylated by AMPK was analysed by
solid-phase sequencing (1000 cpm), MALDI-MS and nanoESI-MS/MS
to identify the phosphorylated residue(s). The three numbers in
parentheses correspond to the peptide mass calculated from the
sequence, measured by MALDI-MS and by nanoESI-MS/MS,
respectively. The cycle numbers were replaced by the amino-acid
sequence established by nanoESI-MS/MS (amino acids not identified
are in parentheses). 
the stimulation of heart glycolysis by ischaemia, which
was also transient and disappeared during prolonged and
severe ischaemia [23]. The transient nature of the phe-
nomenon probably explains our previous failure to
observe an increase in fructose 2,6-bisphosphate concen-
tration in hearts submitted to ischaemia/anoxia for
30 minutes [24].
Perfusion for 10 minutes with 5 µM oligomycin or 3 µM
antimycin, or under anoxic or ischaemic conditions acti-
vated both AMPK (at least 10-fold) and PFK-2 (2–3-fold)
and doubled the concentration of fructose 2,6-bisphos-
phate (Table 1). Maximal effects were already obtained
with 0.5–1 µM of both inhibitors (data not shown). The
extent of activation of AMPK correlated with the increase
in the AMP:ATP ratio (see Supplementary material). In
contrast, perfusion with 5-aminoimidazole-4-carboxamide
(AICA) riboside had no effect on AMPK and PFK-2 activ-
ity, and on fructose 2,6-bisphosphate concentration. AICA
riboside is known to activate AMPK in liver after its phos-
phorylation into AICA ribotide (also called ZMP), an ana-
logue of AMP responsible for AMPK activation [25,26].
However, in hearts perfused with AICA riboside, the con-
centration of ZMP, ZDP and ZTP were barely detectable
(data not shown), in agreement with previous work per-
formed on rabbit cardiomyocytes [27]. The lack of effect
of AICA riboside on AMPK activity in heart differs from
the results reported for isolated papillary heart muscle
cells [13]. Whatever the reason for this discrepancy, we
did not detect any significant accumulation of ZMP, con-
sistent with the lack of AMPK activation.
The kinetic properties of PFK-2 from normoxic or
ischaemic hearts were compared. The Vmax of PFK-2 from
ischaemic hearts was twice that of normoxic hearts. No
significant changes in Km for MgATP and fructose 6-phos-
phate, or in IC50 for magnesium citrate could be detected.
Therefore, ischaemia induces changes in kinetic proper-
ties of PFK-2 in vivo that are similar to those observed
after phosphorylation of His6–PFK-2 by AMPK in vitro
(see Supplementary material).
Activation of AMPK and PFK-2 in cell lines
We first compared the effect of 1 mM AICA riboside or
0.5 µM oligomycin on endogenous AMPK activity in
four different cell lines (CHO, FTO-2B, HEK-293 and
COS-7). AMPK activation by oligomycin was observed in
all cell lines, whereas AICA riboside activated AMPK
(more than twofold) only in FTO-2B and CHO cells (see
Supplementary material and Figure 4a). The failure to
detect an activation of AMPK following incubation with
AICA riboside appears to be due to a lack of accumulation
of ZMP within the cells (D.C., unpublished results), as in
the perfused hearts. 
The effects of AICA riboside or oligomycin on transfected
His6–PFK-2 activity were then studied in FTO-2B and
HEK-293 cells. In such experiments, the treatment lasted
for only 10 minutes and was therefore too short to affect
the enzyme content, as verified by immunoblots. Endoge-
nous PFK-2 activity was unaffected by AICA riboside or
oligomycin treatment (data not shown). Transfection of
His6–PFK-2 in FTO-2B cells resulted in a sevenfold
1250 Current Biology Vol 10 No 20
Figure 3
Activation of (a) AMPK and (b) PFK-2, and
increase in (c) fructose 2,6-bisphosphate
concentration in ischaemic rat hearts. After a
20 min equilibration, rat hearts were perfused
for the indicated periods of time under
normoxic conditions (white squares) or
submitted to a no-flow ischaemia (black
squares) by interrupting the perfusion flow.
(a) Total AMPK activity, (b) PFK-2 activity and
(c) fructose 2,6-bisphosphate concentration
were measured in freeze-clamped hearts.
Inset, isoform-specific AMPK activity was
measured in samples taken after 10 min of
perfusion and immunoprecipitated with anti-
α1 or anti-α2 antibodies. Values are the
means ± SEM for at least four different hearts.
Asterisks indicate values significantly different
(p < 0.01, unpaired t-test) from the
corresponding control value.
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overexpression (endogenous, 13 ± 3 µU/mg protein;
transfected with 10 µg DNA, 97 ± 5 µU/mg protein;
n = 3). Incubation for 10 minutes with 1 mM AICA ribo-
side or 0.5 µM oligomycin increased transfected PFK-2
activity (Figure 4b). In HEK-293 cells, the activity of
transfected His6–PFK-2 was about 60 times that of
endogenous PFK-2 (endogenous, 12 ± 1 µU/mg protein;
transfected with 10 µg  DNA, 706 ± 13 µU/mg protein;
n = 3). In these cells, 0.5 µM oligomycin activated trans-
fected PFK-2 after 10 minutes of incubation (Figure 4b).
This activation was not due to other protein kinases such
as PKB, MAPKAPK-1 and p70S6k because it was not
antagonised by PD 98059 (50 µM), rapamycin (100 nM)
or wortmannin (100 nM), which prevent the activation of
these kinases (Figure 4).
To determine the in vivo phosphorylation site(s) involved in
the oligomycin-induced activation of PFK-2, HEK-293 cells
were transfected with His6–PFK-2. After labelling with
32P, the transfected cells were incubated for 10 minutes
with or without 0.5 µM oligomycin. Immunoprecipitation
and SDS–PAGE of transfected His6–PFK-2 followed by
autoradiography revealed a single 32P-labelled band with
the expected Mr of 61,000 (Figure 5a). Its labelling was
increased about twofold in oligomycin-treated cells. The
labelled band was digested with trypsin and peptides were
separated by reverse-phase HPLC (Figure 5b). The
elution profile from unstimulated cells displayed two
major peaks (peaks 1 and 2) followed by two minor peaks
(peaks 3 and 4). This profile was similar to that previously
described [17]. The first two peaks correspond to peptides
containing phosphorylated Ser522 and Ser528, which may
represent MAP kinase(s) sites and which do not change
PFK-2 activity [17]. Oligomycin increased the labelling of
peak 3 (Figure 5c). The elution time of this peak corre-
sponds to that of the peptide containing phosphorylated
Ser466 in vitro (compare Figures 2b and 5c). The S466E
His6–PFK-2 mutant (10 µg DNA) was also transfected in
HEK-293 cells. Oligomycin did not activate the S466E
His6–PFK-2 (control, 665 ± 15 µU/mg protein; oligomycin,
656 ± 23 µU/mg protein; n = 3). The elution profile of
radioactive peaks obtained with this mutant indicated that
Research Paper  Heart PFK-2 activation by AMPK Marsin et al.    1251
Table 1
Activation of AMPK and PFK-2 and increase in fructose 2,6-bisphosphate concentration and AMP:ATP ratio in hearts submitted to
various conditions.
AMPK activity PFK-2 activity Fructose 2,6-bisphosphate
Condition of perfusion AMP:ATP ratio (mU/mg protein) (µU/mg protein) concentration (pmol/mg protein)
Normoxic control 0.03 ± 0.01 119 ± 10 12.2 ± 0.5 14.3 ± 0.4
Ischaemia 0.25 ± 0.05* 911 ± 87* 25.4 ± 0.6* 46.3 ± 4.4*
Anoxia 0.48 ± 0.04* 1468 ± 162* 27.8 ± 2.7* 44.3 ± 1.9*
AICA riboside 0.04 ± 0.01 114 ± 8 11.8 ± 0.9 14.7 ± 1.5
DMSO control 0.06 ± 0.01 276 ± 63 12.5 ± 0.5 14.3 ± 0.7
Oligomycin 1.32 ± 0.14* 2099 ± 288* 26.5 ± 1.2* 34.8 ± 3.1*
Antimycin 0.55 ± 0.09* 1279 ± 34* 23.3 ± 2.7* 35.5 ± 2.3*
After a 20 min equilibration period, rat hearts were perfused for 10 min
under the following conditions: anoxia (obtained by equilibrating the
perfusion buffer with a 95% N2/5% CO2 gas phase), ischaemia, 5 µM
oligomycin, 3 µM antimycin, 1 mM AICA riboside or control conditions
(normoxia for anoxia, ischaemia and AICA riboside; DMSO for
inhibitors of oxidative phosphorylation). Values are the means ± SEM
for at least four different hearts; *p < 0.01 (unpaired t-test) compared
with the control value.
Figure 4
Activation of (a) endogenous AMPK and 
(b) transfected His6–PFK-2 by AICA riboside
and oligomycin in FTO-2B and HEK-293 cells.
FTO-2B and HEK-293 cells were transfected
with a vector expressing wild-type
His6–PFK-2 (10 µg DNA). The cells were
incubated for 10 min under control conditions
(white columns), with 0.5 µM oligomycin (dark
grey columns) or with 1 mM AICA riboside
(light grey columns) and with inhibitors
(50 µM PD 98059, 100 nM rapamycin and
100 nM wortmannin) as indicated. These
inhibitors were added 20 min before
oligomycin treatment. The content of
His6–PFK-2 was not affected by oligomycin or
AICA riboside, as verified by western blots
(data not shown). The extent (-fold) of
oligomycin-induced activation of AMPK and
PFK-2 is given on top of the columns when
statistically significant (p < 0.01, unpaired
t-test). Values are the means ± SEM for three
different preparations.
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peak 3 was absent and that no other oligomycin-induced
radioactive peak was detected (Figure 5d,e). 
To assess the role of AMPK in the activation of PFK-2 by
oligomycin, the effect of co-expression of PFK-2 with a
catalytically inactive mutant of α1 AMPK (α1DN AMPK)
was studied in HEK-293 cells. Expression of α1DN
AMPK in primary rat hepatocytes acted as a dominant-
negative inhibitor of endogenous AMPK by competing for
the binding of the β and γ subunits [28]. We verified that
transfection with α1DN AMPK abolished the oligomycin-
induced activation of both endogenous and cotransfected
wild-type (α1βγ and α2βγ) AMPK in HEK-293 cells
(Figure 6a).
Having confirmed the dominant-negative character of
α1DN AMPK, we tested whether α1DN AMPK could
interfere with the effect of oligomycin on His6–PFK-2
activation. In the absence of α1DN AMPK, there was a
time-dependent and concomitant activation of both AMPK
and transfected His6–PFK-2 by oligomycin (Figure 6b,c).
Furthermore, immunoblotting with antibody raised
against phosphorylated Ser466 revealed a similar time-
dependent phosphorylation of His6–PFK-2 on Ser466
(Figure 6d). In contrast, when α1DN AMPK was coex-
pressed, phosphorylation and activation of transfected
His6–PFK-2 by oligomycin was almost completely abol-
ished (Figure 6b–d). 
Taken together, these results provide strong evidence that
the oligomycin-induced activation of heart PFK-2 is due
to phosphorylation by AMPK. The data support our
hypothesis that AMPK mediates PFK-2 activation under
conditions leading to ATP depletion in the heart.
Discussion
AMPK activates heart PFK-2 by phosphorylating Ser466.
Our in vitro and in vivo studies fulfil the criteria put
forward by E.G. Krebs [29] to demonstrate that phosphory-
lation of a target protein has physiological relevance. The
experimental evidence can be summarised as follows: first,
PFK-2 is phosphorylated in vitro by AMPK to a significant
extent; second, AMPK-phosphorylated PFK-2 can be
dephosphorylated by PP2A; third, phosphorylation corre-
lates with PFK-2 activation; fourth, AMPK activation in
heart or cells in culture correlates with PFK-2 activation;
fifth, the same site, Ser466, is phosphorylated by AMPK
in vitro and in intact cells; and, finally, PFK-2 activation by
oligomycin in transfected cells is abolished by a dominant-
negative mutant of AMPK. Heart PFK-2 therefore repre-
sents a new substrate of AMPK and is activated by AMPK
in anaerobic conditions. It is noteworthy that PFK-2 is only
1252 Current Biology Vol 10 No 20
Figure 5
(a) Phosphorylation of wild-type His6–PFK-2
and (b–e) HPLC profiles of 32P-labelled
tryptic peptides of wild-type His6–PFK-2 or
the S466E mutant from transfected HEK-293
cells incubated with or without oligomycin.
(a) Transfected His6–PFK-2 from 32P-labelled
HEK-293 cells incubated with or without
oligomycin (10 min) was immunoprecipitated
and subjected to SDS–PAGE and
autoradiography. After tryptic digestion of
immunoprecipitated 32P-labelled (b,c) wild-
type His6–PFK-2 or (d,e) S466E mutant,
peptides were separated by reverse-phase
HPLC using a linear gradient of acetonitrile
(dashed line). The numbered peptides are
defined in the text.
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the second substrate for AMPK known to be activated fol-
lowing phosphorylation, the first being eNOS [18].
AMPK is known to inactivate key enzymes in biosynthetic
pathways, thereby conserving energy. Until recently,
however, AMPK was not known to stimulate ATP produc-
tion. Our results indicate that this could occur under
anaerobic conditions in the heart. The AMPK-mediated
activation of PFK-2 stimulates the flux through PFK-1 by
increasing fructose 2,6-bisphosphate concentration. This
would be expected to lead to a stimulation of ATP pro-
duction through glycolysis. To our knowledge, this is the
first demonstration of protein phosphorylation being
involved in the Pasteur effect. This phenomenon is super-
imposed on the well-known and direct stimulation of
PFK-1 by changes in adenine nucleotide concentrations
(particularly a fall in ATP and a rise in AMP). Therefore,
the increase in AMP:ATP ratio stimulates PFK-1 through
two mechanisms: a direct allosteric stimulation of PFK-1
and an indirect mechanism involving the phosphorylation
of PFK-2 by AMPK.
Activation of PFK-1 and PFK-2 is unable to stimulate
glycolysis by itself [1]. Overall flux can only increase if the
supply of glucose 6-phosphate is also increased. There-
fore, besides PFK-1/PFK-2 activation, the stimulation of
glucose transport by AMPK is an intrinsic part of the
concerted mechanism by which AMPK stimulates heart
glycolysis (Figure 7). 
PFK-2 activation by AMPK is restricted to tissues contain-
ing the heart isozyme of PFK-2. Heart and renal medulla
express the heart isozyme, but this is not the case for liver or
skeletal muscle. The liver and muscle PFK-2 isozymes do
not contain the carboxy-terminal AMPK phosphorylation
site. Therefore, in anoxic livers, no increase in fructose 2,6-
bisphosphate and PFK-2 would be expected, and in fact a
fall in fructose 2,6-bisphosphate content has been observed
[30]. A similar observation was reported in hepatocytes incu-
bated with AICA riboside [31] and in skeletal muscle sub-
mitted to anaerobic contraction [32]. The difference in
regulation between skeletal and cardiac muscle is intriguing
and the reasons for this discrepancy are not known.
However, one would expect PFK-2 activation by anoxia to
hold true for cancer cells that contain the inducible PFK-2
[21] or for the placental PFK-2 isozyme [22]. Our results
indicate that these isozymes contain a carboxy-terminal
sequence that can be phosphorylated by AMPK, possibly to
a lesser extent than heart PFK-2, on the basis of peptide
phosphorylation. Activation of inducible PFK-2 by AMPK
together with induction of this PFK-2 isozyme could
contribute to maintain the high glycolytic rate that is a
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Figure 6
Inhibition of the oligomycin-induced activation of (a,b) AMPK and
(c) His6–PFK-2 in HEK-293 cells cotransfected with the α1DN AMPK
mutant. HEK-293 cells were cotransfected with the different constructs
as indicated. All α AMPK constructs incorporated sequences encoding
the Myc epitope tag. (a) Effect of α1DN AMPK on the oligomycin-
induced activation of endogenous and cotransfected α1βγ and α2βγ
AMPK. These wild-type AMPK isoforms were obtained by
cotransfection of three constructs (encoding α1 AMPK or α2 AMPK,
β AMPK and γ AMPK). To obtain the same amount of Myc-tagged
α AMPK, α1 or α2 AMPK subunit was overexpressed in control cells.
The amount (µg) of transfected DNA is indicated. Cells were incubated
with or without 0.5 µM oligomycin for 10 min. AMPK activity was
measured after immunoprecipitation with anti-α1 or anti-α2 antibodies
for endogenous AMPK and with anti-Myc antibody for transfected
AMPK. Results are the means for three different preparations.
Immunoblots of transfected AMPK (anti-Myc antibody) are shown. (b,c)
Effect of α1DN AMPK (shaded squares) on oligomycin-induced
activation of (b) total AMPK activity and (c) cotransfected His6–PFK-2
activity. The α1 AMPK subunit was taken as control (unshaded
squares). Cells were incubated with 0.5 µM oligomycin for the indicated
periods of time. The triangles indicate endogenous PFK-2 activity in
non-transfected cells. Values are the means for three different cell
preparations. Amount of transfected DNA: His6–PFK-2, 5 µg; α1
AMPK, 5 µg; α1DN AMPK, 5 µg. (d) Immunoblots of phosphorylated
heart PFK-2 (anti-phospho-S466 antibody), transfected PFK-2 (anti-His
antibody, Sigma), and transfected AMPK (anti-Myc antibody,
Boehringer) were performed on samples taken from the cells shown in
(b,c). The times are indicated below the blots. Asterisks indicate values
significantly different (p < 0.01, unpaired t-test) from the corresponding
zero time; crosses indicate values significantly different (p < 0.01,
unpaired t-test) from cells without the α1DN construct.
characteristic feature of many tumours (Warburg effect)
[21]. In conclusion, the activation of heart PFK-2 by AMPK
and possibly of other PFK-2 homologues offers a new inter-
pretation for the hypoxia-induced stimulation of glycolysis.
Materials and methods
Materials
Mutant (S466E) and wild-type recombinant heart PFK-2/FBPase-2
(His6–PFK-2, previously called BH1(His)6 [17]), total AMPK [33] and
α1βγ and α2βγ AMPK isoforms [19] were purified as described. The
constructs encoding wild-type and mutant His6–PFK-2 [17], and α1,
α2, β1 and γ1 AMPK subunits [34] have been described. A rabbit poly-
clonal antibody (anti-phospho-S466 antibody) was raised against the
phosphorylated peptide RRN(Sp)FTP (corresponding to residues
463–469 of heart PFK-2 in which Ser466 was phosphorylated). Pep-
tides called MR6 (459PVRMRRNSFT468 of heart PFK-2), MR47
(455PLMRRNSVT463 of inducible PFK-2 [21]) and SAMS, a synthetic
peptide derived from ACC [20], were synthesised by V. Stroobant
(Ludwig Institute for Cancer Research, Brussels, Belgium). 
In vitro studies
Methods for measurement of phosphorylation and dephosphorylation
of His6–PFK-2 by purified AMPK and PP2A, respectively, the changes
in kinetic properties induced by phosphorylation, and the identification
of phosphorylation sites have been described [16,17]. 
In vivo studies
Hearts from fed male Wistar rats were perfused (Langendorff method)
as described [24]. Perfusion conditions are detailed in the legends to
the figures and tables. At the indicated times, hearts were freeze-
clamped and stored at –80°C. The frozen hearts were homogenised
(Ultra-Turrax) at 0–4°C in 5 volume (v/w) of buffers used for the assay.
For AMPK measurements, the buffer contained 50 mM Hepes at
pH 7.6, 50 mM KCl, 50 mM NaF, 5 mM sodium pyrophosphate, 1 mM
EDTA, 1 mM EGTA, 1 mM dithiothreitol, 5 mM β-glycerophosphate,
100 nM microcystin and protease inhibitors (4 µg/ml leupeptin, 1 mM
benzamidine hydrochloride, 1 µg/ml aprotinin, 0.7 µg/ml pepstatin,
0.2 mM phenylmethanesulfonyl fluoride and 4 µg/ml trypsin inhibitor).
For PFK-2 assays, the buffer contained 20 mM Hepes at pH 7.5,
30 mM KCl, 20 mM NaF, 5 mM EGTA, 5 mM EDTA, 1 mM dithiothre-
itol, 100 nM microcystin, 0.1 mM fructose 6-phosphate, 0.3 mM
glucose 6-phosphate and the protease inhibitors indicated above.
High-speed supernatants (20,000 × g, 30 min) were taken for the
assays. For measurements of the AMP:ATP ratio and fructose 2,6-bis-
phosphate, the hearts were homogenised in perchloric acid [31] or
alkali [35], respectively.
Cell culture studies
The transfection protocols were a modified calcium phosphate proce-
dure [17] for HEK-293 cells and the lipofectamine method (following
instructions provided by the manufacturer GIBCOBRL) for FTO-2B cells.
When confluent, the cells were deprived of serum for 16 h and then
incubated as described in the legends to the figures and tables. At the
end of the incubation period, the medium was rapidly removed and the
cells were immediately lysed in 0.8 ml ice-cold lysis buffer (50 mM
Hepes at pH 7.5, 0.2% Triton X-100, 50 mM KF, 1 mM potassium phos-
phate, 5 mM EDTA, 5 mM EGTA, 1 µM microcystin, 1 mM Na3VO4,
15 mM β-mercaptoethanol, 1 mM PMSF, 1 mM benzamidine hydrochlo-
ride and 1 µg/ml leupeptin), scraped, frozen in liquid nitrogen and stored
at –80°C. Phosphorylation and identification of the phosphorylated
residue of transfected PFK-2 was realised as described [17]. In experi-
ments using the dominant-negative AMPK (α1DN AMPK), transfection
of wild-type α1, which is not active if expressed in the absence of the β
and γ subunits [19], was used as a control. This control gave results
similar to those obtained following transfection with PFK-2 without
cotransfected wild-type α1 AMPK (data not shown).
Enzyme and metabolite measurements
Total AMPK activity was assayed after precipitation with 10% (w/v)
polyethylene glycol 6000, whereas the activity of the α1βγ or α2βγ iso-
forms of endogenous AMPK was assayed after immunoprecipitation
with anti-α1 or anti-α2 antibodies [19]. All αAMPK constructs incorpo-
rated sequences encoding the Myc tag. The activity of these transfected
AMPKs was assayed after immunoprecipitation with anti-Myc antibodies
(Boerhinger). In all cases, conditions were set up to obtain maximal
immunoprecipitation, and the activity was linear as a function of time and
of protein concentration. AMPK activity was measured by phosphoryla-
tion of the synthetic peptide SAMS in the presence of 0.2 mM AMP [4].
PFK-2 was measured in a 20% (w/v) polyethylene glycol 6000 precipi-
tate (perfused hearts) or in crude extract (cultured cells). Unless other-
wise stated, PFK-2 activity [36] was measured at pH 7.1 with 1 mM
fructose 6-phosphate, 3 mM glucose 6-phosphate and 5 mM MgATP.
Fructose 2,6-bisphosphate was measured as described [35] and purine
nucleotides were measured after their separation by HPLC [31].
Other methods
Proteins were measured by Coomassie Blue staining or by the nin-
hydrin reaction after total alkaline hydrolysis, with bovine serum albumin
as a standard. Kinetic constants were calculated by computer fitting of
the data to a hyperbola describing the Michaelis–Menten equation by
non-linear least-square regression. One unit of enzyme activity corre-
sponds to the formation of 1 µmol (PFK-2) or 1 nmol (protein kinases
and PP2A) of product per minute under the assay conditions.
Supplementary material
Supplementary material including a figure showing the correlation
between AMPK activity and AMP:ATP ratio in perfused rat hearts sub-
mitted to anaerobic conditions, and four tables presenting changes in
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Figure 7
Mechanism of stimulation of heart glycolysis by AMPK under
anaerobic conditions. Green arrow, activation by covalent
modification; dashed green arrow, allosteric stimulation; pPFK-2,
phosphorylated form of heart PFK-2. The question mark indicates an
indirect and still unknown mechanism.
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kinetic properties of heart PFK-2 in vitro and in vivo, a comparison of
the kinetic properties of the α1βγ and α2βγ AMPK isoforms on syn-
thetic peptides and AMPK activation in different cell lines is available at
http://current-biology.com/supmat/supmatin.htm.
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